Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

Completed

• Conditions: Choroidal Neovascularization

• Registration Number: NCT00417703
• Lead Sponsor: Oklahoma State University Center for Health Sciences

Brief Summary

This study will quantify the intraocular pressure elevation in the immediate time period following intravitreous injection. With more widespread use of intravitreous injections in patients that may require several injections per year, it is important to document the sudden increase in intraocular pressure, including the maximum intraocular pressure and the time required for the intraocular pressure to return to baseline. This data may be useful in stimulating additional studies to evaluate the long term ocular effects of repeated intravitreous injections.

We hypothesize that the intraocular pressure increases significantly following intravitreous injection and then returns to baseline during the initial thirty minutes following ranibizumab injection.

Detailed Description

We will assess the trend of intraocular pressure immediately following intravitreal injection of ranibizumab 0.5 mg (0.05 mL) by taking serial intraocular pressure readings every five minutes for thirty minutes after injection. This study is a prospective descriptive data collection consisting of measuring intraocular pressure immediately following intraocular injection, and at 5, 10, 15, 20, 25, and 30 minutes following injection of ranibizumab 0.5 mg.

Study Timeline

• Study Start: 2007-01
• Study First Submitted: 2007-01-03
• Study First Submitted QC: 2007-01-03
• Study First Posted: 2007-01-04
• Status Verified: 2008-01
• Primary Completion: 2008-01
• Study Completion: 2008-01
• Last Update Submitted: 2008-01-22
• Last Update Posted: 2008-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

1. Male or Female Patients >18 years of age
2. Patients will have documented choroidal neovascular membranes on fluorescein angiogram and/or optical coherence tomography
3. Requiring treatment or maintenance therapy for choroidal neovascular membrane
4. Able and willing to provide written informed consent

Exclusion Criteria

1. History of arterial occlusive disease of the eye.
2. History of advanced glaucoma.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Retina Support Services, Inc; 🇺🇸 Tulsa, Oklahoma, United States